ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

April 13, 2007

NCI, NINCDS Need Patients For Brain, Breast Studies

September 10, 1982

NCI Staff Recommends Moving Cooperative Groups Into DCT, Increase Funding, Switch Emphasis

July 4, 1975

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007

Lurie Center At Northwestern Wins Core Grant Renewal.

December 7, 2001

Emory’s Winship Cancer Institute Wins NCI Cancer Center Designation

April 17, 2009